Optimizing delayed scan time for FDG PET: Comparison of the early and late delayed scan

Chen, Yu Mei; Huang, Gang; Sun, Xiao; Liu, Jing; Chen, Tao; Shi, Yi; Wan, Liang

doi:10.1097/mnm.0b013e3282f4d389

Cited by 42 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many previous studies have performed the delayed FDG PET scan around 2 h after the injection of FDG [17,18,21,22,31,32] or around 3 h after the injection [16,19]; however, no optimized delayed scan time-point has yet been recommended. According to a previous study by Chen et al [33], the diagnostic value of a 110-min scan imaging was higher than that of a 233-min scan imaging.…”

Section: Discussionmentioning

confidence: 85%

Detection of Hepatic Metastases Using Dual-Time-Point FDG PET/CT Scans in Patients with Colorectal Cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 85%

Detection of Hepatic Metastases Using Dual-Time-Point FDG PET/CT Scans in Patients with Colorectal Cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Recently, Chen et al [31] explored the most appropriate time for a delayed scan by comparing early and late delayed 18 F FDG PET scans. They performed first scan at the mean time of 64 min after 18 F FDG injection; the second scan began approximately 110 min after injection, and the third scan was obtained approximately 233 min after 18 F FDG injection in 80 patients with 148 suspected lesions.…”

Section: Discussionmentioning

confidence: 99%

Limited diagnostic and predictive values of dual-time-point 18F FDG PET/CT for differentiation of incidentally detected thyroid nodules

Kim

Jeon

et al. 2011

Ann Nucl Med

View full text Add to dashboard Cite

show abstract

“…Tumor-specific studies would be useful to assess the optimal timing of imaging for tumors, which could have differing levels of hexokinase/glucose-6-phosphatase ratio (eg, hematological malignancy, sarcoma, breast and other carcinoma subtypes). Therefore, the most appropriate time for a delayed scan should be defined for each kind of neoplasm 81 ; moreover, the method of SUV calculation should be standardized, as well as the criteria for quantitative thresholds to define lesions as malignant, for example, for the lung nodules. Finally, larger prospective studies may be helpful to better evaluate the clinical role of DP FDG-PET/CT imaging in oncology patients, in particular taking into account any possible resulting change in management.…”

Section: Discussionmentioning

confidence: 99%

Use of Dual-Point Fluorodeoxyglucose Imaging to Enhance Sensitivity and Specificity

Schillaci

2012

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

Positron emission tomography (PET) and positron emission tomography/computed tomography imaging with fluorodeoxyglucose (FDG) are widely used as a powerful evaluation modality in oncological nuclear medicine not only for detecting tumors but also for staging and for therapy monitoring. Nevertheless, there are numerous causes of FDG uptake in benign processes seen on PET images. In fact, the degree of FDG uptake is related to the cellular metabolic rate and the number of glucose transporters. FDG accumulation in tumors is due, in part, to an increased number of glucose transporters in malignant cells. However, FDG is not specific for neoplasms: a similar situation exists in inflammation; activated inflammatory cells demonstrate increased expression of glucose transporters. Therefore, there is growing interest in improving the specificity of FDG-PET in patients with cancer. Preliminary studies showed that in several neoplasms, the uptake of FDG continues to increase for hours after radiopharmaceutical injection, and this difference in the time course of FDG uptake could be useful to improve the accuracy of PET to distinguish benign lesions from malignant ones. Also in experimental cultures, dual-point acquisition (early at 40-60 minutes postinjection and delayed at 90-270 minutes) demonstrated that it is able to differentiate inflammatory from neoplastic tissue. In general, inflammatory tissue is expected to reduce FDG uptake as the time goes by, whereas the uptake in the neoplastic lesions is supposed to be increasing. There is evidence in the recent literature of the clinical usefulness of dual-time-point FDG-PET imaging in a wide variety of malignancies, including those of head and neck, lung, breast, gallbladder, cervix, liver, and in brain tumors. A lesion is likely to be malignant if the standard uptake value increases over time, whereas it is likely to be benign if the standard uptake value is stable or decreases. It is worth noting that in many of these studies, dual-time-point PET improved not only the specificity but also the sensitivity in assessing breast, pulmonary, liver, and other tumors because of increased lesion-to-background ratio, as a consequence of FDG washout from the surrounding normal tissues and increasing neoplastic uptake. Semin Nucl Med 42:267-280

show abstract

Optimizing delayed scan time for FDG PET: Comparison of the early and late delayed scan

Abstract: The retention index values in the two delayed phases have good relativity. The diagnostic value of early delayed imaging is higher than that of late delayed imaging. An early delayed scan, according to our research, should be recommended in clinical practice.

Cited by 42 publications

References 11 publications

Detection of Hepatic Metastases Using Dual-Time-Point FDG PET/CT Scans in Patients with Colorectal Cancer

Detection of Hepatic Metastases Using Dual-Time-Point FDG PET/CT Scans in Patients with Colorectal Cancer

Limited diagnostic and predictive values of dual-time-point 18F FDG PET/CT for differentiation of incidentally detected thyroid nodules

Use of Dual-Point Fluorodeoxyglucose Imaging to Enhance Sensitivity and Specificity

Contact Info

Product

Resources

About